NanoCarb-GLYCOVAX joint workshop + First network meeting

NanoCarb has successfully held its first Network Meeting at the CNR Research Area in Milan from the 14th to the 17th May 2019. Part of the event was held together with the European Training Networks (ETNs) GLYCOVAX.

From the 14th to the 16th May 2019, both ETNs have organised a series of common lectures for their Early-Stage Researchers (ESRs) (see programme below). GLYCOVAX and NanoCarb ESRs have attended lectures on vaccine formulation and nanomedicine from high-profile academic lecturers, but also from leading pharmaceutical companies such as GSK Vaccines, Midatech Pharma Spain and Ludger Ltd. Workshop summaries will follow in the next few days.

Thursday 16th May Workshop speakers

The NanoCarb ESRs had two sessions where they had an open discussions with the Glycovax ESR on the challenges on doing a PhD. The session was managed by our trainers Dr Daniel Spencer from Ludger Ltd and Helen Williamson from Horizons Unleashed. As the GLYCOVAX training programme is coming to an end and NanoCarb has recently started, these meetings were the occasion for NanoCarb ESRs to learn from the experience of their peers in GLYCOVAX.

Joint discussion between GLYCOVAX and NanoCarb ESRs

On the 16th and 17th May, NanoCarb ESRs had the opportunity to introduce themselves to the NanoCarb consortium and to get in touch with organisations where they will carry out secondments.

NanoCarb ESRs

Workshops in Nanovaccines:

Time Activity Speaker(s)
09:00 – 09:30 Introduction on vaccines and nanotechnology Prof Luigi Lay, University of Milan Dr Laura Polito, Italian National Research Council
09:30 – 10:15 Vaccine formulation: an overview Dr Francesco Berti, GSK Vaccines
10:15 – 11:00 Discovery of new generation of adjuvants and delivery of adjuvanted vaccines Barbara Christiane Baudner, GSK Vaccines
11:30 – 12:15 Synthetic multivalent ligands for biomacromolecule targeting Prof Francesco Sansone, University of Parma
12:15 – 13:00 OMV and Carriers Dr Francesca Micoli, GSK Vaccines

Workshops in Nanomedicine:

Time Activity Speaker(s)
09:00 – 09:45 Cancer treatment: hurdles and hopes from a clinician’s perspective Dr Luca Toschi, Humanitas Cancer Center
09:45 – 10:30 Cancer nanotechnology: hopes and challenges   Dr Zeljka Kreptic, University of Salford Manchester
11:00 – 11:20 Gold glyconanoparticles: smallest particles in biomedical use for targeted delivery to tumour and disease sites Dr Africa Barrientos, Midatech Pharma Spain
11:20 – 11:40 Lost in translation, nanoparticle characterization in biological fluid Dr Marco Monopoli, Royal College of Surgeons in Ireland
11:40 – 12:00 In vitro – in vivo implementation of the preclinical studies in nanomedicine Dr Paolo Bigini, Mario Negri Institute for Pharmacological Research
12:00 – 12:20 Biological activity of glycans Dr Daniel Spencer, Ludger Ltd
12:20 – 12:50 The market of drugs: light and shadow   Silvio Garattini, Mario Negri Institute for Pharmacological Research
12:50 – 13:00 Closing remarks Prof Luigi Lay, University of Milan